FDA Approves New Version of PrEP—Just Two Shots A Year
The FDA has approved lenacapavir as a form of pre-exposure prophylaxis (PrEP), offering a new option for HIV prevention requiring only two shots per year.
Two Studies Show Doxy PEP is a Winning Strategy
Two studies published in this month’s JAMA Internal Medicine offer encouraging findings about the use of Doxy PEP.
Preventing HIV with Just Two Shots a Year? A New Study Shows This is Possible
Remarkable results in a Phase III PrEP trial with women and adolescent girls in Africa—two injections per year effectively prevented all HIV infection.
Update to PrEP Recommendations Include Long-Acting Shot
The USPSTF recently released updated recommendations on Pre-Exposure Prophylaxis for preventing the sexual transmission of HIV. The recommendations add additional medications, including a long-acting injectable.